Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan

Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan

George G Sokos, 1 Amresh Raina 2 1Department of Medicine, Division of Cardiology, West Virginia School of Medicine, Morgantown, WV, USA; 2Pulmonary Hypertension Program, Section of Heart Failure/Transplant/MCS & Pulmonary Hypertension, Allegheny General Hospital, AGH McGinnis Cardiovascula...

Full description

Bibliographic Details
Main Authors: Sokos GG, Raina A
Format: Article
Language:English
Published: Dove Medical Press 2020-01-01
Series:Vascular Health and Risk Management
Subjects:
angiotensin receptor/neprilysin inhibitor
cardiovascular death
patient outcomes
treatment recommendations.
Online Access:https://www.dovepress.com/understanding-the-early-mortality-benefit-observed-in-the-paradigm-hf--peer-reviewed-article-VHRM

Internet

https://www.dovepress.com/understanding-the-early-mortality-benefit-observed-in-the-paradigm-hf--peer-reviewed-article-VHRM

Similar Items